Director, Clinical Imaging, Translational Sciences-Immunology

About the role

The Director, Clinical Imaging will provide strategic and scientific leadership for the development, validation, and delivery of imaging-derived endpoints to enable high-impact decision-making across the Immunology portfolio, with a primary focus on Gastrointestinal (GI) diseases. The role is US-based (Spring House, PA or Cambridge) and sits within the Translational Science organization, operating in a highly matrixed environment across Immunology Disease Area Strategy, Clinical Development, Data Sciences, Regulatory, and operational functions.

Responsibilities

• Lead the GI-focused imaging measurement strategy across Immunology assets, spanning early through late-phase clinical development.
• Shape endpoint strategies integrating imaging measurements to support mechanistic understanding, proof-of-concept, and decision-enabling outcomes including regulatory.
• Partner with Disease Area Strategy and Translational Science leaders to ensure alignment with portfolio priorities and clinical development plans.
• Contribute to investment cases, governance discussions, and portfolio reviews, articulating value, readiness, and risk.
• Provide scientific oversight and accountability for imaging endpoints across early- and late-phase clinical trials.
• Ensure methods have an operationally delivery model to scale.
• Partner with clinical and operational partners across the organization, Data Sciences, and external vendors/CROs to ensure on-time, high-quality delivery.
• Support regulatory interactions related to imaging endpoints.
• Identify and advance next-generation imaging technologies with clear trajectories to GI pipeline impact from novel molecular methods through to AI-based structural endpoints.
• Lead the integration of AI-enabled analytics for imaging and digital endpoints, in close partnership with the Data Science organization.
• Co-develop AI-based solutions (e.g. automated image analysis, quantitative feature extraction, digital signal interpretation) to improve scalability, reproducibility, and decision-making in high impact areas.
• Translate emerging methods into pragmatic clinical solutions balancing innovation with feasibility and timelines.
• Partner closely with the Imaging and Digital Health team colleagues to drive innovation and delivery across disease areas.
• Operate effectively in a complex, global matrix environment and influence to guide strategy.
• Serve as a trusted scientific advisor to project teams, DAS leadership, and senior stakeholders.
• Communicate complex technical concepts with clarity and impact to diverse audiences.
• Mentor and develop scientists and matrix partners, contributing to a culture of scientific excellence and accountability.

Requirements

• PhD or MD, or equivalent advanced degree in a relevant scientific or clinical discipline.
• Minimum 10 years of experience in pharmaceutical or biotech R&D.
• Demonstrated experience applying imaging in interventional clinical trials.
• Proven ability to balance innovation with reliable execution in complex development environments.
• Exceptional written, verbal and presentation skills.
• Strong track record of working effectively in highly matrixed global organizations.
• In-depth knowledge of Gastrointestinal diseases, including Crohn’s disease and ulcerative colitis.
• Experience working in close partnership with AI/ML teams to develop or deploy analytics for clinical trials.
• Familiarity with AI-enabled image analysis, digital biomarker pipelines, or quantitative imaging workflows.
• Exposure to regulatory interactions involving imaging endpoints.
• Experience managing external partnerships with technology vendors, CROs and academic collaborators.

Qualifications

• Establish clear ownership and strategic direction for GI imaging endpoints aligned to GI Disease Area Strategy and clinical development teams.
• Establish an effective operating model with the Data Science organization to deliver AI-enabled analytics for imaging and digital endpoints.
• Exhibit disciplined scientific and portfolio decision-making, including refinement or discontinuation of approaches where pipeline value is not compelling.
• Be recognised by project teams and senior stakeholders as a trusted scientific and strategic leader who balances innovation with delivery.